Boston, MA 的 神經膠質瘤 臨床試驗
20 項針對 神經膠質瘤 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
招募中1/2 期
- Research Site, Boston
MCT for the Harvard/UCSF ROBIN Center
招募中
- Brigham and Women's Hospital, Boston
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
招募中2 期
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
Targeted Pediatric High-Grade Glioma Therapy
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
招募中2 期
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
招募中2 期
- Dana-Farber Cancer Institute, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
招募中1 期
- Massachusetts General Hospital Cancer Center, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
招募中早期第 1 期歡迎健康志工
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
招募中2 期
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
招募中1/2 期
- Dana Farber Cancer Institute, Boston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
招募中早期第 1 期
- Dana-Farber Cancer Institute, Boston
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
招募中1 期
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
CUE-102 in Recurrent Glioblastoma
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
招募中
- Massachusetts General Hospital Cancer Center, Boston
ASCENT Intervention for Brain Tumor Patients
招募中
- Massachusetts General Hospital Cancer Center, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
招募中觀察性研究
- Massachusetts General Hospital, Boston
其他城市的 神經膠質瘤 試驗
- New York City, NY25 項研究
- Houston, TX23 項研究
- Washington, DC19 項研究
- Philadelphia, PA16 項研究
- Columbus, OH15 項研究
- Miami, FL15 項研究
- San Francisco, CA14 項研究
- Chicago, IL13 項研究
- Durham, NC12 項研究
- Seattle, WA11 項研究
- St. Louis, MO10 項研究
- Aurora, CO10 項研究
Boston 的其他研究
- 乳癌112 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）85 項研究
- 轉移性癌症63 項研究
- 大腸直腸癌63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。